Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.
The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.
Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.
Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Paul R. Smolevitz
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreThyssen'sche Handelsgesellschaft has acquired h/p/cosmos sports & medical GmbH
Thyssen’sche Handelsgesellschaft mbH (THG), a German strategic holding company, has acquired a majority stake in h/p/cosmos sports & medical GmbH. Founder and former sole shareholder Franz Harrer, who built h/p/cosmos into a global leader in niche medical and sports diagnostics equipment, remains invested as a minority partner. THG will support the company’s international growth and innovation plans, while the existing management team continues to run the business.
Learn more